Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AbbVie

5 Standout Healthcare Dividend Stocks to Consider Now

Amid healthcare’s enduring importance and increasing demand for its products and services, here are five dividend-paying healthcare stocks to consider now.

Barchart

AbbVie Is 'Firing On All Cylinders,' But Its Stock Doesn't Show That

AbbVie is "firing on all cylinders," an analyst said Friday after the firm beat first-quarter estimates. But AbbVie stock fell.

Investors Business Daily

Stock Index Futures Climb on Upbeat Big Tech Earnings, U.S. Inflation Data Looms

June S&P 500 E-Mini futures (ESM24) are up +0.63%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.86% this morning as upbeat quarterly results from tech titans Alphabet and Microsoft boosted sentiment, while investors geared up for the release of the Fed’s preferred inflation gauge.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Merck (MRK) vs. AbbVie (ABBV): Which Pharma Stock Will Drive Earnings Growth?

The pharmaceutical industry is expected to expand significantly due to the ever-rising global medical needs and technological advances. In this scenario, let’s analyze the better investment option between popular pharma stocks, Merck &Co (MRK) and AbbVie (ABBV).

StockNews.com

Fake Botox injections have sickened 22, hospitalized 11, CDC warns

The CDC warned doctors about "counterfeit or mishandled" Botox injections that have caused clusters of illness in the U.S.

LiveScience

The Bad News Heading Into AbbVie's First-Quarter Earnings Report

AbbVie stock has slumped 9% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, Humira.

Investors Business Daily

Fake Botox has sickened patients nationwide. Here's what to know — and what to avoid

Public health authorities are investigating reports of counterfeit injections sickening 19 people across nine states. Experts say getting bona fide Botox starts with finding a trustworthy provider.

WEKU

Read news from The Economist, FT, and more,
with one subscription

19 Botched Botox Cases Reported Across 9 States: CDC, FDA Investigate

Officials said that all the incidents involved women who reported sick following the administration of counterfeit Botox injections of AbbVie or those who received injections from unlicensed or untrained individuals in non-healthcare environments.

Medical Daily

3 Defensive Stocks for 'Sell in May' Season

Investors can consider adding defensive stocks, such as AbbVie and Verizon, to their equity portfolios in 2024 to help shield against heightened stock market volatility.

Barchart

Patients in England to be offered daily pill that can halve migraine frequency

Nice approves first oral treatment with Atogepant that can prevent chronic and episodic migraines

The Guardian - UK

Alvotech Aims To Break Open The World's Most Notorious Pharma Market

Alvotech's 2024 plans include several product launches around the world through various partners, but the forthcoming introduction of SIMLANDI® in the U.S. is in a market that is truly in the spotlight.

International Business Times

3 Passive Income Stocks To Scoop Up Now

These three stocks have earned the title of Dividend Kings by consistently increasing dividends for at least 50 years.

Barchart

3 Pharma Stocks Fueling Investor Enthusiasm

The pharmaceutical industry is expected to expand rapidly due to growing global healthcare needs and advancements in technology. Therefore, fundamentally strong pharma stocks Merck (MRK), AbbVie (ABBV), and GSK plc (GSK) might be ideal additions to your portfolio. Read on.

StockNews.com

MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test

Biotech stock MoonLake popped Monday after the company said its experimental psoriatic arthritis treatment beat out AbbVie's Humira.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

4 Top Dividend Kings to Earn Passive Income

Dividend Kings are companies with a long history of paying and increasing shareholder dividends, which signals strong financial health for investors looking to build a steady stream of passive income.

Investors Business Daily

AbbVie Stock Clears Key Benchmark, Hitting 80-Plus RS Rating

A Relative Strength Rating upgrade for AbbVie shows improving technical performance.

Investors Business Daily

Drug Maker AbbVie Stock Sees RS Rating Jump To 81

AbbVie shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Investors Business Daily

AbbVie Expects Two Of Its Biggest Drugs To Bring In $27 Billion In 2027. And Neither One Is Humira.

AbbVie raised its long-term guidance for Skyrizi and Rinvoq, two key immunology drugs, on Friday. AbbVie stock inched higher.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

AbbVie (ABBV) Earnings Preview: Buy or Sell Opportunities

While AbbVie (ABBV) saw a decrease in net revenues and EPS in the last reported quarter, it raised its 2023 adjusted EPS guidance range. With the company gearing up to report fourth-quarter 2023 results tomorrow, is the stock worth buying today? Keep reading.

Investors Business Daily

AbbVie Stock Moves With Rising Relative Strength, Still Room To Grow

AbbVie shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

WEKU

A new test could save arthritis patients time, money and pain. But will it be used?

Stories of chronic pain, drug-hopping, and insurance meddling are all too common among patients with rheumatoid arthritis. Precision medicine offers new hope.

StockNews.com

Are These 3 Pharma Stocks Smart Buys for Bullish Investors?

The pharmaceutical industry's outlook looks promising, given robust healthcare spending worldwide and the rapid adoption of advanced digital technologies. Amid this, let’s find out if pharma stocks AbbVie (ABBV), Collegium Pharmaceutical (COLL), and Merck (MRK) are ideal buys now. Read on to know more….

The Independent UK

Stock market today: Asian shares are mostly higher ahead of a key US jobs report

Asian shares are mostly higher ahead of a U.S. jobs report after Wall Street rose Thursday to snap its first three-day losing streak since Halloween

Fortune

What it really takes to be a great place to work

There’s no one-size-fits-all model, but it can be done at virtually any organization.

StockNews.com

Analyzing December Profit Potential for the Top 4 Pharma Stocks

The global pharmaceutical market is witnessing robust growth, fueled by an escalating demand for healthcare services amid a burgeoning and aging population. Hence, fundamentally solid pharma stocks Novartis (NVS), Bristol-Myers Squibb (BMY), AbbVie (ABBV), and Taro Pharmaceutical (TARO) might be solid buys for gains this month. Read more.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.